Gabapentin Tablet
Product Images NDC 60760-943

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-943). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (A4928566 6bc9 4a2a A368 C68afc402368 01)

Chemical structure diagram of the active ingredient gabapentin showing its molecular framework including a cyclohexane ring and functional groups with amine and carboxyl substituents.*

FDA Label Image

Figure 1 (A4928566 6bc9 4a2a A368 C68afc402368 02)

Line chart depicting mean pain scores over an 8-week period comparing placebo to Gabapentin at 3600 mg/day. The x-axis shows weeks from baseline to week 8, segmented into 4-week dose titration and 4-week fixed dose periods. The y-axis displays mean pain scores ranging from 0 to 10, with Gabapentin showing a decreasing pain score trend compared to placebo.*

FDA Label Image

Figure 2 (A4928566 6bc9 4a2a A368 C68afc402368 03)

A line graph showing mean pain scores over 7 weeks for placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, starting from baseline to week 7, and the y-axis represents mean pain score from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, with both Gabapentin doses showing reduced pain scores compared to placebo.*

FDA Label Image

Figure 3 (A4928566 6bc9 4a2a A368 C68afc402368 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing response rates for two studies. Study 1 compares placebo (12%) and Gabapentin 3600 mg (29%). Study 2 compares placebo (14%), Gabapentin 1800 mg (32%), and Gabapentin 2400 mg (34%). Statistical significance is indicated by asterisks.*

FDA Label Image

Figure 2 (A4928566 6bc9 4a2a A368 C68afc402368 05)

A scatter plot chart showing percentage difference on the vertical axis and daily dose in mg on the horizontal axis. It compares three studies labeled as Study a, Study b, and Study c, indicated by different colored squares, at various gabapentin daily doses from about 600 mg to 1800 mg.*

FDA Label Image

943 (Gabapentin 800mg 90ct 60760 943 90)

Gabapentin Tablets USP 800 mg oral tablet, quantity 90, labeled by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label includes NDC 60760-943-90, directions for usual dosage and storage conditions, and manufacturer information for Strides Pharma Science Limited, Tamil Nadu, India. It features instructions to keep the container tightly closed and dispense with a Medication Guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.